Testing a standard approach for pleuropulmonary blastoma, with or without topotecan
Part of Cancer clinical trials.
This trial compares a standard surgery and chemotherapy plan for type I pleuropulmonary blastoma (PPB) to adding the drug topotecan for types II and III PPB. The goal is to see if the extra drug helps shrink tumors and improve outcomes for children with more advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger.
- You must have a newly diagnosed type I, Ir, II, or III PPB (a rare lung tumor) diagnosed within the last 60 days.
- If you have type II or III PPB, your kidney and liver function must be within certain limits based on age, checked within 7 days before starting treatment.
- Your heart function must be normal, as shown by an echocardiogram or similar test within 21 days.
- You cannot have had chemotherapy for PPB before this trial.
- If you are HIV-positive, your viral load must be undetectable and you must not be on certain HIV medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Hear when a new Pleuropulmonary Blastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.